Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

被引：7
|
作者：
Huang, Linjuan [1 ,2 ,3 ,4 ]
Zhang, Jing [1 ,2 ,3 ,4 ]
Deng, Youling [1 ,2 ,3 ,4 ]
Wang, Hao [4 ,5 ,6 ]
Zhao, Piao [1 ,2 ,3 ,4 ]
Zhao, Guozhi [1 ,2 ,3 ,4 ]
Zeng, Wei [4 ,7 ]
Wang, Yonghui [4 ,8 ]
Chen, Connie [4 ]
Wagstaff, William [4 ]
Haydon, Rex C. [4 ]
Reid, Russell R. [4 ,9 ]
He, Tong-Chuan [4 ,10 ]
Shen, Le [4 ,10 ]
Luu, Hue H. [4 ]
Zhao, Ling [1 ,2 ,3 ,4 ]
机构：
[1] Chongqing Med Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Chongqing 400046, Peoples R China
[2] Chongqing Med Univ, Affiliated Hosp 1, Dept Orthopaed Surg, Chongqing 400046, Peoples R China
[3] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing 400046, Peoples R China
[4] Univ Chicago, Med Ctr, Dept Orthopaed Surg & Rehabil Med, Mol Oncol Lab, Chicago, IL 60637 USA
[5] Chongqing Med Univ, Minist Educ, Sch Lab Med, Key Lab Diagnost Med, Chongqing 400016, Peoples R China
[6] Chongqing Med Univ, Sch Lab Med, Chongqing 400016, Peoples R China
[7] Jianghan Univ, Affiliated Hosp 2, Dept Neurol, Wuhan 430050, Hubei, Peoples R China
[8] Shanghai Jiao Tong Univ, Sch Med, Dept Clin Lab Med, Shanghai 200000, Peoples R China
[9] Univ Chicago, Med Ctr, Dept Surg Sect Plast Surg, Lab Craniofacial Suture Biol & Dev, Chicago, IL 60637 USA
[10] Univ Chicago, Med Ctr, Dept Surg, Chicago, IL 60637 USA
来源：
GENES & DISEASES | 2023年 / 10卷 / 04期
基金：
美国国家卫生研究院;
关键词：
Chemotherapy resistance; Cisplatin; Drug repurposing; Niclosamide; Ovarian cancer; MESENCHYMAL STEM-CELLS; BMP9-INDUCED OSTEOGENIC DIFFERENTIATION; SUPPRESSES TUMOR-GROWTH; WNT/BETA-CATENIN; ANTIHELMINTHIC NICLOSAMIDE; OSTEOBLAST DIFFERENTIATION; GENE-EXPRESSION; INHIBITION; PATHWAY; PROLIFERATION;
D O I：
10.1016/j.gendis.2022.12.005
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Ovarian cancer (OC) is one of the most lethal malignancies of the female reproduc-tive system. OC patients are usually diagnosed at advanced stages due to the lack of early diag-nosis. The standard treatment for OC includes a combination of debulking surgery and platinum-taxane chemotherapy, while several targeted therapies have recently been approved for maintenance treatment. The vast majority of OC patients relapse with chemoresistant tu-mors after an initial response. Thus, there is an unmet clinical need to develop new therapeu-tic agents to overcome the chemoresistance of OC. The anti-parasite agent niclosamide (NA) has been repurposed as an anti-cancer agent and exerts potent anti-cancer activities in human cancers including OC. Here, we investigated whether NA could be repurposed as a therapeutic
引用
收藏
页码：1687 / 1701
页数：15
相关论文
共 50 条
  • [31] EFFECT OF CADMIUM ON HUMAN OVARIAN-CANCER CELLS WITH ACQUIRED CISPLATIN RESISTANCE
    LEE, KB
    PARKER, RJ
    REED, E
    CANCER LETTERS, 1995, 88 (01) : 57 - 66
  • [32] Experimental study on the mechanism of cisplatin resistance and its reversion in human ovarian cancer
    Liang Zhengdong
    Bian Duhong
    CHINESE MEDICAL JOURNAL, 1996, (05) : 355 - 355
  • [33] Human ovarian cancer and cisplatin resistance: Possible role of inhibitor of apoptosis proteins
    Li, JL
    Feng, Q
    Kim, JM
    Schneiderman, D
    Liston, P
    Li, M
    Vanderhyden, B
    Faught, W
    Fung, MFK
    Senterman, M
    Korneluk, RG
    Tsang, BK
    ENDOCRINOLOGY, 2001, 142 (01) : 370 - 380
  • [34] Combined use of cisplatin plus natural killer cells overcomes immunoresistance of cisplatin resistant ovarian cancer
    Choi, Seung Hee
    Jung, Daun
    Kim, Ki Yeon
    An, Hee Jung
    Park, Kyung-Soon
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2021, 563 : 40 - 46
  • [35] Niclosamide Analogs for Treatment of Ovarian Cancer
    Haygood, Christen L. Walters
    Arend, Rebecca C.
    Gangrade, Abhishek
    Chettiar, Somsundaram
    Regan, Nicholas
    Hassmann, Christopher J., II
    Li, Pui-Kai
    Hidalgo, Bertha
    Straughn, John Michael, Jr.
    Buchsbaum, Donald J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (08) : 1377 - 1385
  • [36] Niclosamide analogs for treatment of ovarian cancer
    Haygood, Christen L. Walters
    Arend, Rebecca C.
    Li, Pui-Kai
    Li, Yonghe
    Kurpad, Chandrika
    Gangrade, Abhishek
    Straughn, John M.
    Buchsbaum, Donald
    CANCER RESEARCH, 2014, 74 (19)
  • [37] Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines
    Wang, W
    Ke, SN
    Chen, G
    Gao, QL
    Wu, SF
    Wang, SX
    Zhou, JF
    Yang, XK
    Lu, YP
    Ma, D
    ONCOLOGY REPORTS, 2004, 12 (06) : 1365 - 1370
  • [38] AURKA Mediates Resistance to Cisplatin and Its Inhibition By Alisertib Overcomes Therapeutic Resistance in Gastric Cancer
    Wang, Lihong
    Arras, Janet
    Katsha, Ahmed M.
    Zaika, Alexander
    Belkhiri, Abbes
    El-Rifai, Wael
    GASTROENTEROLOGY, 2016, 150 (04) : S110 - S110
  • [39] ORMAPLATIN SENSITIVITY RESISTANCE IN HUMAN OVARIAN-CANCER CELLS MADE RESISTANT TO CISPLATIN
    PARKER, RJ
    VIONNET, JA
    BOSTICKBRUTON, F
    REED, E
    CANCER RESEARCH, 1993, 53 (02) : 242 - 247
  • [40] Expression of glutathione S-transferase pi and cisplatin resistance in human ovarian cancer
    Kase, H
    Kodama, S
    Tanaka, K
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1996, 6 (03) : 241 - 245
12345